NCT03183557招募中2 期
Examination of Bone Metabolism and Bone Mineral Density by Zoledronic Acid in Primary and Secondary Osteoporosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Bone mineral density
研究概览
简要总结
There has been no comparative data between Zoledronic acid and Zoledronic acid combined with active vitamin D in primary and secondary osteoporosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Osteoporotic patients who want to take zoledronic acid
排除标准
- •Patients who are allergic to zoledronic acid or vitamin D
- •Patients who are pregnant or breast-feeding
- •Patients who have not taken zoledronic acid for the last 2 years
研究组 & 干预措施
ZA plus VD
Active Comparator
干预措施: "Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®" (Drug)
ZA alone
Active Comparator
干预措施: "Zoledronic acid", "Reclast®" (Drug)
结局指标
主要结局
Bone mineral density
时间窗: Change from Baseline Values at 1 year
次要结局
未报告次要终点
研究者
Yukio Nakamura
Associate professor at Shinshu University
Shinshu University
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With OsteoporosisOsteoporosisNCT00404820Novartis604
招募中
2 期
Efficacy of Oral Ibandronate in OsteoporosisOsteoporosisNCT03186131Shinshu University100
已完成
不适用
Effect of Zolendronate in patients of celiac diseaseCTRI/2015/06/005863Dr Sanjay Kumar Bhadada50
已完成
不适用
A study to compare zoledronic acid and calcium and vitamin D, with placebo (dummy) and calcium and vitamin D, on the frequency of hip fractures and of new spinal fractures in post-menopausal women with osteoporosisMusculoskeletal Diseases: OsteoporosisMusculoskeletal DiseasesOsteoporosisISRCTN16703536Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)7,400
进行中（未招募）
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment - ProBONE IIEUCTR2004-002832-24-DEovartis Pharma GmbH